Q-omics provides the consensus-scored NKX3-1 profile across patient tissues and cancer cell-line models. NKX3-1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, NKX3-1 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, NKX3-1 RNA expression shows 17,265 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight LUAD, KICH, and KIRP as cancer lineages where NKX3-1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NKX3-1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NKX3-1 survival associations across molecular data types. NKX3-1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NKX3-1 RNA expression–survival associations across cancer types. High NKX3-1 expression shows unfavorable associations in LUAD, MESO, GBM, KIRC and THCA, but favorable associations in BRCA. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify LUAD as the clearest survival context for NKX3-1 RNA expression.
This table summarizes NKX3-1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for NKX3-1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NKX3-1 shows lower tumor expression in KICH, KIRC, LIHC, THCA and COAD and higher tumor expression in PRAD. The KICH box plot shows higher NKX3-1 RNA expression in normal versus tumor tissue (log2 FC = −1.107, t-test p < 0.001).
This table shows molecular features associated with NKX3-1 in patient tissues and cancer cell lines. In patient samples, NKX3-1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, NKX3-1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and CNS.
